AU2018246214B2 - Niraparib compositions - Google Patents

Niraparib compositions Download PDF

Info

Publication number
AU2018246214B2
AU2018246214B2 AU2018246214A AU2018246214A AU2018246214B2 AU 2018246214 B2 AU2018246214 B2 AU 2018246214B2 AU 2018246214 A AU2018246214 A AU 2018246214A AU 2018246214 A AU2018246214 A AU 2018246214A AU 2018246214 B2 AU2018246214 B2 AU 2018246214B2
Authority
AU
Australia
Prior art keywords
composition
indazole
piperidin
phenyl
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018246214A
Other languages
English (en)
Other versions
AU2018246214A1 (en
Inventor
John Chaber
Jennifer R. Foley
Arlene E. Mckeown
George Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Tesaro Inc
Original Assignee
Merck Sharp & Dohme LLC
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63676949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018246214(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme LLC, Tesaro Inc filed Critical Merck Sharp & Dohme LLC
Publication of AU2018246214A1 publication Critical patent/AU2018246214A1/en
Application granted granted Critical
Publication of AU2018246214B2 publication Critical patent/AU2018246214B2/en
Priority to AU2021245223A priority Critical patent/AU2021245223A1/en
Assigned to MERCK SHARP AND DOHME CORP., TESARO, INC. reassignment MERCK SHARP AND DOHME CORP. Amend patent request/document other than specification (104) Assignors: TESARO, INC.
Assigned to TESARO, INC., MERCK SHARP & DOHME LLC reassignment TESARO, INC. Request to Amend Deed and Register Assignors: MERCK SHARP AND DOHME CORP., TESARO, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018246214A 2017-03-27 2018-03-27 Niraparib compositions Active AU2018246214B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021245223A AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021245223A Division AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Publications (2)

Publication Number Publication Date
AU2018246214A1 AU2018246214A1 (en) 2019-11-07
AU2018246214B2 true AU2018246214B2 (en) 2021-07-08

Family

ID=63676949

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018246214A Active AU2018246214B2 (en) 2017-03-27 2018-03-27 Niraparib compositions
AU2021245223A Abandoned AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021245223A Abandoned AU2021245223A1 (en) 2017-03-27 2021-10-08 Niraparib compositions

Country Status (14)

Country Link
US (3) US11091459B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600314A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512350A (cg-RX-API-DMAC7.html)
KR (1) KR20200014736A (cg-RX-API-DMAC7.html)
CN (1) CN110944638A (cg-RX-API-DMAC7.html)
AU (2) AU2018246214B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020211A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058375C (cg-RX-API-DMAC7.html)
EA (1) EA201992177A1 (cg-RX-API-DMAC7.html)
IL (1) IL269630A (cg-RX-API-DMAC7.html)
MX (1) MX2019011496A (cg-RX-API-DMAC7.html)
SG (1) SG11201909011PA (cg-RX-API-DMAC7.html)
TW (1) TWI761476B (cg-RX-API-DMAC7.html)
WO (1) WO2018183354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
JP2023524794A (ja) 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
JP2026517228A (ja) 2023-05-17 2026-05-28 テサロ, インコーポレイテッド がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005818A1 (en) * 2016-06-29 2018-01-04 Tesaro, Inc. Methods of treating ovarian cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
MX2010004028A (es) * 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
EP2240466B1 (en) * 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク. 多環系化合物の新規形態
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
EP3424909A1 (en) 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) * 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005818A1 (en) * 2016-06-29 2018-01-04 Tesaro, Inc. Methods of treating ovarian cancer

Also Published As

Publication number Publication date
TW201840315A (zh) 2018-11-16
SG11201909011PA (en) 2019-10-30
CA3058375C (en) 2025-05-06
AU2021245223A1 (en) 2021-11-04
BR112019020211A2 (pt) 2020-04-22
CN110944638A (zh) 2020-03-31
TWI761476B (zh) 2022-04-21
IL269630A (en) 2019-11-28
EP3600314A1 (en) 2020-02-05
EA201992177A1 (ru) 2020-02-25
US11091459B2 (en) 2021-08-17
CA3058375A1 (en) 2018-10-04
KR20200014736A (ko) 2020-02-11
US20230416223A1 (en) 2023-12-28
AU2018246214A1 (en) 2019-11-07
WO2018183354A1 (en) 2018-10-04
US20210403448A1 (en) 2021-12-30
US20200017462A1 (en) 2020-01-16
MX2019011496A (es) 2020-01-23
JP2020512350A (ja) 2020-04-23
US11673877B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
US11673877B2 (en) Niraparib compositions
US11896717B2 (en) Sustained-release dosage forms of ruxolitinib
US11730725B2 (en) Niraparib formulations
AU2018329202B2 (en) Methods for making and using endoxifen
KR20100093057A (ko) 리카르바제핀 아세테이트를 포함하는 경구 투여형
US20150335609A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN110662534A (zh) 包含(e)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-n-叔丁基苯甲酰胺的药物组合物和药物剂型,其制备方法、治疗方法及用途
EP1572158A1 (en) A new oral immediated release dosage form
EP2976067B1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
TW202327588A (zh) 治療神經膠質母細胞瘤之方法
CN116322653A (zh) 包括酞嗪酮衍生物的药物组合物
WO2012039691A2 (en) Synergic effect
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
CN108853033A (zh) 一种喹硫平药物制剂

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO WU, GEORGE; CHABER, JOHN; MCKEOWN, ARLENE E. AND FOLEY, JENNIFER R.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD APPLICANT MERCK SHARP AND DOHME CORP.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ U, GEORGE; CHABER, JOHN; MCKEOWN, ARLENE E. AND FOLEY, JENNIFER R.

HB Alteration of name in register

Owner name: MERCK SHARP AND DOHME CORP.

Free format text: FORMER NAME(S): TESARO, INC.

Owner name: TESARO, INC.

Free format text: FORMER NAME(S): TESARO, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: TESARO, INC.

Free format text: FORMER NAME(S): TESARO, INC.; MERCK SHARP AND DOHME CORP.

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): TESARO, INC.; MERCK SHARP AND DOHME CORP.